Homestead Associates In Research | Homestead, FL

Research site

(Unclaimed)

Location

27535 S Dixie Highway, Homestead, Florida, United States of America

Site insights

Top conditions

Top treatments

SAR441566

MK-6024

SEL-212

Semaglutide

Teriflunomide

RO7790121

Apalutamide

Remibrutinib

MTX

Inebilizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 25 total trials

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatit...

Enrolling

Metabolic Dysfunction-associated Steatotic Liver Disease

Non-alcoholic Fatty Liver Disease

Combination Product: Efinopegdutide

Combination Product: Placebo

A Phase 2a Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythemat...

Enrolling

Active Refractory Rheumatoid Arthritis

Systemic Lupus Erythematosus

Drug: Blinatumomab

Drug: Inebilizumab

A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults

The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-...

Enrolling

COVID-19

Biological: CVXGA (CVXGA50)

Biological: COMIRNATY®

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD)

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Active, not recruiting

Crohn's Disease

Biological: JNJ-78934804

Biological: Golimumab

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-1)

This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) co...

Enrolling

Moderately to Severely Active Ulcerative Colitis

Drug: Afimkibart

Drug: Placebo

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with mod...

Enrolling

Alzheimer Disease

Drug: Placebo

Drug: KarXT

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis (empacific)

This study will evaluate the safety and efficacy of empasiprubart compared with placebo in adult participants with dermatomyositis (DM).The study dur...

Enrolling

Myositis

Dermatomyositis

Other: Placebo IV

Biological: Empasiprubart IV

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.

Enrolling

Moderate to Severe Genital Psoriasis

Drug: Tildrakizumab 100 mg

Drug: Placebo

Locations recently updated

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. (SPECIFI-CD)

This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety o...

Enrolling

Crohn's Disease

Drug: SAR441566

Drug: SAR441566 matching Placebo

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus peglot...

Active, not recruiting

Gout

Drug: Methotrexate

Biological: Pegloticase